INDIANAPOLIS: Eli Lilly and Company’s (NYSE: LLY) innovative obesity treatment, Zepbound™ (tirzepatide) injection, has received the green light from the U.S. Food and Drug Administration (FDA). This inventive solution, a first-of-its-kind therapy, targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound aims to assist adults struggling with obesity (BMI of 30 kg/m2 or higher) or those dealing with weight-related health issues such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease, in shedding weight and maintaining a healthy lifestyle.
The FDA’s decision was based on findings from the extensive phase 3 SURMOUNT-1 and SURMOUNT-2 trials. Participants in SURMOUNT-1, comprising 2,539 adults with obesity or weight-related medical problems (excluding diabetes), experienced noteworthy weight loss when using Zepbound in combination with diet and exercise, showcasing an average weight reduction of 48 lb. at the highest dosage and 34 lb. at the lowest dosage, compared to 7 lb. in the placebo group.
Notably, a substantial portion of patients administered the highest dose of Zepbound saw an impressive reduction of over 58 lb. (25% of their body weight), highlighting the potential of this treatment for significant....READ MORE
Weight gain and obesity has been described as an epidemic and a complex problem in the United States. Previous research has linked poor diet to weight gain and high body...
INDIANAPOLIS: Eli Lilly and Company’s (NYSE: LLY) innovative obesity treatment, Zepbound™ (tirzepatide) injection, has received the green light from the U.S. Food and Dru...
A virtual marketplace leading your business into the future
